Alligator Bioscience announced the completion of patient enrolment in the ongoing OPTIMIZE-1 Phase 2 trial of the company's lead asset mitazalimab in 1st line metastatic pancreatic cancer. Thanks to this acceleration in patient enrolment, Alligator confirms it expects to report top-line data in the beginning of First Quarter 2024. The open-label, multi-center study is assessing the safety and efficacy of mitazalimab (CD40 mAb) in combination with chemotherapy, mFOLFIRINOX, in previously untreated patients with metastatic pancreatic ductal adenocarcinoma.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.132 SEK | +5.01% | +17.18% | +64.30% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+64.30% | 77.57M | |
+48.64% | 54.63B | |
-6.44% | 39.92B | |
+37.07% | 38.82B | |
+14.28% | 26.86B | |
-11.17% | 26.22B | |
-21.40% | 18.78B | |
+25.64% | 12.21B | |
+0.96% | 12.16B | |
+27.04% | 11.94B |
- Stock Market
- Equities
- ATORX Stock
- News Alligator Bioscience AB
- Alligator Bioscience Announces Completion of Patient Enrolment in Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer and Confirms Timeline for Top-Line Data in First Quarter 2024